文献速递心力衰竭与心肌病

ICAM1 p.K56M变异与慢性肾脏病患者心力衰竭风险

The ICAM1 p.K56M variant and risk of heart failure in chronic kidney disease: the Chronic Renal Insufficiency Cohort study.
PubMed 文献 · Heart · 2025-05-02

在慢性肾功能不全队列(CRIC)的1267名黑人参与者中,37%携带至少一个ICAM1 rs5491(p.K56M)等位基因。中位随访10.3年期间,每增加一个rs5491等位基因与射血分数保留的心力衰竭(HFpEF)发病风险显著相关(HR 1.35,95%CI 1.03-1.76,p=0.029),但与整体心衰或射血分数降低的心衰(HFrEF)无关。

要点

  • ICAM1 p.K56M变异与CKD患者HFpEF风险增加相关。
  • 该变异与整体心衰及HFrEF风险无显著关联。
  • 在CKD黑人患者中,rs5491携带率约为37%。

核心结论

  • ICAM1 p.K56M变异与慢性肾脏病患者发生HFpEF的风险增加特异性相关。

研究设计与样本

  • 研究为慢性肾功能不全队列(CRIC)中的前瞻性队列分析,纳入1267名基线无心力衰竭的黑人参与者,平均年龄57±11岁,51%女性,平均eGFR 45±15 mL/min/1.73 m2,基线eGFR范围20-70 mL/min/1.73 m2。

主要发现

  • 1267名黑人参与者中464人(37%)携带至少一个rs5491等位基因。
  • 中位随访10.3年(IQR 4.7-15.0年),共发生309例整体心衰住院,其中HFpEF 160例,HFrEF 111例,射血分数未知心衰38例。
  • 每增加一个rs5491等位基因与HFpEF发病显著相关(HR 1.35,95%CI 1.03-1.76,p=0.029)。
  • rs5491与整体心衰发病无显著关联(HR 1.14,95%CI 0.93-1.39,p=0.20)。
  • rs5491与HFrEF发病无显著关联(HR 0.76,95%CI 0.53-1.10,p=0.15)。

临床怎么用

  • 在慢性肾脏病黑人患者中,检测ICAM1 rs5491变异可能有助于识别HFpEF高风险个体。

局限性

  • 研究仅纳入黑人参与者,结果外推至其他种族人群需谨慎。
  • 为观察性队列研究,不能确立因果关系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Intercellular adhesion molecule-1 (ICAM-1) is a cell-surface protein that facilitates inflammation through leucocyte adhesion. Approximately 35% of Black individuals carry at least one copy of an ICAM1 missense variant (rs5491; p.K56M), which has been associated with increased risk of heart failure (HF) with preserved ejection fraction (HFpEF). Whether the risk of HFpEF conferred by rs5491 extends to individuals with chronic kidney disease (CKD), a cohort at high risk for HF, is unknown. AIMS: We investigated the association between rs5491 and the incidence of HF in CKD. METHODS: We estimated associations of rs5491 with incident HF and HF subtypes among Black individuals who were free from HF at baseline in the Chronic Renal Insufficiency Cohort (CRIC). The CRIC study recruited individuals who were 21-74 years old with estimated glomerular filtration rate (eGFR) of 20-70 mL/min/1.73 m2 at baseline. RESULTS: Among 1267 Black participants (mean age 57±11 years, 51% female, mean eGFR 45±15 mL/min/1.73 m2), 464 (37%) had at least one copy of rs5491. During a median follow-up of 10.3 years (IQR: 4.7-15.0 years), there were 309 incident overall HF hospitalisations (160 HFpEF, 111 HF with reduced ejection fraction (HFrEF) and 38 HF with unknown ejection fraction). Each additional rs5491 allele was significantly associated with incident HFpEF (HR 1.35, 95% CI 1.03 to 1.76, p=0.029). The rs5491 variant was not associated with incident overall HF (HR 1.14, 95% CI 0.93 to 1.39, p=0.20) or incident HFrEF (HR 0.76, 95% CI 0.53 to 1.10, p=0.15). CONCLUSION: The ICAM1 p.K56M variant is specifically associated with increased risk of incident HFpEF among individuals with CKD.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Culler, Zelnick, Mehta, et al. The ICAM1 p.K56M variant and risk of heart failure in chronic kidney disease: the Chronic Renal Insufficiency Cohort study. Heart. 2025. PMID: 39915070. doi:10.1136/heartjnl-2024-325205

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。